Real World Study on Compliance of Subcutaneous Specific Immunotherapy in Patients with Allergic Rhinitis and/or Bronchial Asthma in the Pearl River Delta Region
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2022.0103
- VernacularTitle:珠三角地区变应性鼻炎和/或支气管哮喘患者皮下特异性免疫治疗依从性的真实世界研究
- Author:
Yu-lin JIANG
1
;
Xin-yue WANG
2
;
Jun TANG
3
;
Yan-min BAO
4
;
Gui-lan WANG
5
;
Jun BAI
6
;
Zhen-peng LIAO
7
;
Ya-ting LI
1
Author Information
1. Department of Pediatrics， The Third Affiliated Hospital of Sun Yat-sen University， Guangzhou 510630， China
2. Department of Otorhinolaryngology Head and Neck Surgery， The Third Affiliated Hospital of Sun Yat-sen University， Guangzhou 510630，China
3. Department of Otorhinolaryngology Head and Neck Surgery， Foshan First People's Hospital， Foshan 528000， China
4. Department of Respiratory Medicine， Shenzhen Children's Hospital， Shenzhen 518038， China
5. The Second Clinical Medical School of Southern Medical University， Zhongshan 528403， China
6. Foshan Maternity & Child Healthcare Hospital， Foshan 528000， China
7. Department of Otorhinolaryngology Head and Neck Surgery， The Fifth Affiliated Hospital of Sun Yat-sen University， Zhuhai 519000， China
- Publication Type:Journal Article
- Keywords:
subcutaneous specific immunotherapy;
compliance;
allergic rhinitis;
bronchial asthma;
Pearl River Delta
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2022;43(1):18-26
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the causes of discontinuation of subcutaneous allergen immunotherapy （SCIT） in patients with allergic rhinitis （AR） and / or bronchial asthma （BA） in the Pearl River Delta region， and to improve the compliance of these patients. MethodsIt was a retrospective， multi-center real world study. Patients with AR and / or BA receiving SCIT in six hospitals in the Pearl River Delta region from January 2015 to December 2020 were recruited. The clinical data of all patients were collected， and the patients with abscission were followed up by telephone. ResultsIn this study， 1 244 patients who received SCIT were included. A total of 427 patients stopped SCIT before 3 years （34.3%）. Children， married patients and patients with positive family history of allergy and total immunoglobulin E （tIgE） > 200 U / mL showed relatively good compliance （P<0.05）， while more patients of AR alone stopped SCIT before 3 years than patients of AR complicated with BA （P<0.05）. Patients with high symptom score and drug score before treatment had better compliance （P<0.001）. A total of 279 cases （65.3%） of the non-adherence group were followed by telephone. The first three reasons for discontinuing treatment were the treatment did not achieve the expected effect （115 cases， 41.2%）， factors pertaining to learning and daily life （74 cases， 26.5%） and adverse reactions （29 cases， 10.4%）. The number of patients stopping SCIT decreased gradually with time； the proportion of patients who discontinued treatment due to adverse reactions in the first year of treatment was higher than that in the second and third years （P<0.05）. ConclusionFailure to achieve the expected effect was the primary reason for poor compliance of patients receiving SCIT and discontinuation mainly occurred on the early stage of the treatment. The supervision from family members is helpful to improve the compliance， suggesting that individualized measures need to be taken to reduce the loss of SCIT.
